Deutsche Bank AG Acquires New Shares in Neogen Corporation $NEOG

Deutsche Bank AG acquired a new stake in Neogen Corporation (NASDAQ:NEOG) in the 2nd quarter, Holdings Channel reports. The firm acquired 376,245 shares of the company’s stock, valued at approximately $3,382,000.

Other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Neogen in the second quarter valued at $11,404,000. State of Wyoming purchased a new stake in shares of Neogen in the 2nd quarter worth about $222,000. GSA Capital Partners LLP acquired a new stake in Neogen in the 2nd quarter valued at about $657,000. Oppenheimer Asset Management Inc. acquired a new stake in Neogen in the 2nd quarter valued at about $156,000. Finally, Amundi purchased a new position in Neogen during the 1st quarter valued at about $105,000. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Neogen Trading Up 0.5%

Neogen stock opened at $11.70 on Thursday. The stock has a market cap of $2.55 billion, a PE ratio of -390.00, a P/E/G ratio of 4.59 and a beta of 1.77. The stock has a 50-day moving average price of $10.37 and a 200 day moving average price of $9.85. Neogen Corporation has a 52 week low of $4.90 and a 52 week high of $12.85. The company has a current ratio of 3.82, a quick ratio of 2.91 and a debt-to-equity ratio of 0.38.

Neogen (NASDAQ:NEOG) last released its earnings results on Thursday, July 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. The company had revenue of $225.30 million for the quarter, compared to analyst estimates of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.82) EPS. Equities research analysts predict that Neogen Corporation will post 0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on NEOG shares. Weiss Ratings upgraded shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Piper Sandler raised shares of Neogen from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $13.00 to $14.00 in a research note on Wednesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $12.00.

More Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.